(Total Views: 530)
Posted On: 07/06/2024 7:48:02 PM
Post# of 148905
SKYSCRAPER-06...a study that randomized patients to receive either Tirogolumab and Roche's checkpoint inhibitor Tecentrig OR Merck & Co.'s KEYTRUDA and Chemo.
Roche found the survival rate favored the KEYTRUDA regimen at the First Interim Analysis.
The assessment of (PFS) generated a hazard rate of 1.27...Anything above 1. indicates the Control group performed better than the Investigational Treatment. ALL indications suggest KEYTRUDA patients are living LONGER. Roche at closing down 2%.
Roche found the survival rate favored the KEYTRUDA regimen at the First Interim Analysis.
The assessment of (PFS) generated a hazard rate of 1.27...Anything above 1. indicates the Control group performed better than the Investigational Treatment. ALL indications suggest KEYTRUDA patients are living LONGER. Roche at closing down 2%.
(3)
(0)Scroll down for more posts ▼
